Understanding the physiological consequences of biased signalling mediated by the glucagon-like peptide-1 receptor

胰升糖素样肽1受体是治疗2型糖尿病和肥胖症的主要靶点。然而，针对这种受体的药物的开发是具有挑战性的，因为不同配体的激活可以导致不同的信号偏差，这一范式对生理后果的了解有限。该项目将解决这一关键的知识差距，并可能允许开发具有更好治疗结果的新药。

The glucagon-like peptide 1 receptor is a major target for treatment of Type 2 diabetes and obesity. However, the development of drugs targeting this receptor is challenging as activation by different ligands can result in distinct signalling biases, a paradigm for which there is limited understanding of the physiological consequences. This project will address this critical knowledge gap and may allow for development of novel drugs with improved therapeutic outcomes.